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Although several studies have shown that the serum levels of
osteoprotegerin (OPG) are significantly elevated in patients
affected with atherosclerotic lesions in coronary and peripher-
al arteries,the cellular source and the role of OPG in the phys-
iopathology of atherosclerosis are not completely defined.
Therefore,we aimed to investigate the potential contribution of
mesenchymal stem cells in the production/release of OPG.
OPG was detectable by immunohistochemistry in aortic and
coronary atherosclerotic plaques, within or in proximity of inti-
mal vascular smooth muscle cells (SMC). In addition, bone
marrow mesenchymal stem cell (MSC)-derived vascular SMC
as well as primary aortic SMC released in the culture super-
natant significantly higher levels of OPG with respect to MSC-
derived endothelial cells (EC) or primary aortic EC. On the
other hand,in vitro exposure to full-length human recombinant
OPG significantly increased the proliferation rate of aortic SMC
cultures, as monitored by bromodeoxyuridine incorporation.
Taken together, these data suggest that OPG acts as an
autocrine/paracrine growth factor for vascular SMC, which
might contribute to the progression of atherosclerotic lesions.
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A
therosclerosis is a form of chronic low-grade
inflammation resulting from interaction
between modified lipoproteins, monocyte-
derived macrophages and vascular smooth muscle
cells (SMC) (Libby, 2002). Although the prevalent
view is that intimal vascular SMC found in athero-
sclerotic plaques derive from cells migrating from
the tunica media of the same artery (Libby,2002),
accumulating data indicate that also bone marrow
(BM) mesenchymal stem cells (MSC), also known
as multipotent stromal cells, have the potential to
migrate in sites of vascular injury or inflammation
and to differentiate into vascular SMC
(Hillebrands et al., 2001, Li et al., 2001).
Several studies have clearly demonstrated that
the serum levels of the soluble member of the TNF-
receptor super-family osteoprotegerin (OPG) are
elevated in patients with coronary or carotid artery
disease, especially those with clinically unstable
atherosclerotic plaques (Jono  et al., 2002,
Schoppet et al.,2003,Secchiero et al.,2006a,Shin
et al., 2006, Abedin et al., 2007, Avignon et al.,
2007,Gulbiken et al.,2007,Kadoglu et al.,2008a,
Omland et al., 2008). Despite the fact that neither
the cellular source nor the physiological and patho-
logical effects of elevated serum levels of OPG are
well understood,a possible pathogenic link between
elevated levels of OPG and inflammation has been
suggested by recent in vitro studies of our and oth-
ers research groups (Zauli et al., 2007, Mangan et
al. 2007).
Therefore, in order to assess the potential contri-
bution of MSC in the pathogenesis of atherosclero-
sis, we have evaluated the release of OPG in the
culture supernatants of BM-derived MSC differen-
tiating along the vascular SMC or endothelial cell
(EC) lineages.In addition,we have investigated the
effect of recombinant human OPG on aortic SMC
proliferation.
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Immunohistochemical detection of OPG
Samples of human ascending aortas and coro-
nary vessels with atherosclerotic plaques were
obtained from the Thoracic Surgery Department of
University of Udine, as approved by the local
research ethics committee.All specimens were fixed
with 4% formaldehyde, paraffin-embedded and cut
in serial sections of 5 µm.Tissue morphology was
evaluated by hematoxylin and eosin staining.
Immunohistochemical detection of OPG was per-
formed by using anti-human OPG Ab (clone
69127; R&D Systems, Minneapolis, MN) and the
Super Sensitive TMPolymer HRP IHC detection
system (Bio Genex, San Ramon, CA), according to
the manufacturer’s instructions. 3,3 diaminobenzi-
dine (DAB) was used as a chromogen, with subse-
quent nuclear counterstaining with hematoxylin.
Staining evaluation was essentially qualitative by
visual inspection of the samples by microscope.
Cell cultures
BM MSC, obtained from BM samples as previ-
ously described (Beltrami et al., 2007), were cul-
tured on fibronectin-coated dishes in expansion
medium containing 10% FBS. In order to induce
MSC-differentiation into SMC and EC, MSC were
exposed to standardized differentiation-inducing
conditions, as previously described (Beltrami et al.,
2007). Expression of lineage-specific markers was
monitored by immunofluorescence analysis with
anti-von Willebrand Factor and anti-α-smooth
muscle actin (SMA; Dako, Copenhagen, Denmark)
Abs. Primary human aortic vascular EC and SMC
were obtained by Lonza (Walkersville, MD) and
used between passages 4 and 8. OPG released in
culture supernatants was measured by using a
sandwich-type enzyme-linked immunosorbent assay
(ELISA) kit, purchased from Alexis Biochemicals
(Lausen, Switzerland). The sensitivity of the kit
used was 2.8 pg/mL and the intra- and inter-assay
coefficients of variation were 9% and <10%,
respectively. For cell cycle analysis, SMC were
made in a quiescent state by using serum-reduced
(0.1% FBS) medium, treated with recombinant
OPG (R&D Systems), and then incubated with 5-
bromodeoxyuridine (BrdU; Sigma, Saint Louis,
MO). Next, anti-BrdU Ab bounded to BrdU incor-
porated into newly synthesized DNA was detected
by fluorescein isothiocyanate-conjugated secondary
Ab, as described (Secchiero et al., 2006b). Cells
were stained with propidium iodide (PI) and ana-
lyzed by flow cytometry; live cells were gated tight-
ly using forward and side scatter, as described
(Vitale et al., 1997).
Statistical analysis
Comparison of group means was performed by
Bonferroni and Student’s T test methods.
Statistical significance was defined as p<0.05.
Results
OPG is expressed in vascular SMC of atherosclerotic
aortic and coronary plaques 
Immunohistochemical analysis demonstrated
very low levels of OPG immunostaining in normal
vessels (Figure 1 A). On the other hand, a striking
OPG staining was observed in sections of aortic
and coronary plaques, mainly confined to the
fibrous cap (Figure 1 A). A strong cellular
immunoreactivity in the atherosclerotic lesions was
accompanied by a faint OPG expression in the
interstitial space,according to the fact that OPG is
a secreted protein (Zauli and Secchiero, 2006). A
parallel immunohistochemical analysis performed
on serial histological sections with α-smooth mus-
cle actin (SMA) Ab indicated a preponderance of
vascular SMC in the atherosclerotic fibrous cap
(Figure 1 B). In particular, a good correspondence
was observed between the elongated cells express-
ing OPG and cells identified as vascular SMC
(Figure 1 B).
Bone marrow MSC-derived SMC and primary aortic
SMC release high levels of OPG 
Since it has been previously established that BM
MSC can differentiate into either vascular EC or
SMC (Hegner  et al., 2005, Kashiwakura  et al.,
2003), we next investigated the ability of MSC-
derived SMC and EC to produce and release OPG
in culture (Figure 2). Undifferentiated MSC (day
0) released detectable amounts of OPG in their
culture supernatants.While induction of differenti-
ation along the endothelial lineage did not substan-
tially modulate the amount of OPG released, the
production/release of OPG showed a progressive
and sustained increase paralleling the degree of
SMC differentiation (Figure 2). Consistently with
these findings, proliferating human aortic SMC
released in culture supernatant significantly
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aortic EC (Figure 2). Moreover, in agreement with
recent findings demonstrating that recombinant
OPG stimulates the proliferation of human pul-
monary SMC (Lawrie et al., 2008), we could con-
firm that recombinant OPG also stimulates the
proliferation of aortic SMC (data not shown).
Thus, vascular SMC represent the major cell type
involved in the production of OPG in atherosclerot-
ic lesions and therefore OPG could act as a
paracrine/autocrine growth factor for vascular
SMC.
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Figure 1. OPG expression in
SMC of human atherosclerot-
ic plaques. (A) immunohisto-
chemical detection of OPG in
samples of human ascending
aortas with or without (nor-
mal) atherosclerotic plaque.
FC, Fibrous cap; LC, Lipidic
core. (B) comparison of
immunohistochemical stain-
ing of a plaque performed
with α α-smooth muscle actin
(SMA) and OPG Abs indi-
cates a good correspon-
dence between the elongat-
ed cells expressing OPG and
the SMC of atherosclerotic
fibrous cap (FC). Scale bar:
100 µ µm. Representative pic-
tures are shown.
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Previous studies have shown that the expression
and release of OPG by vascular cells is markedly
up-regulated in response to inflammatory
cytokines, such as TNF-α and platelet-derived
growth factor (Zhang et al., 2002, Olesen et al.,
2005). Conversely, OPG production is inhibited by
PPAR-γ ligands (Fu et al., 2002, Kadoglou et al.,
2008b),agents associated with anti-inflammatory
and anti-atherogenic effects in vitro and in vivo.
In this context, our current demonstration that
BM MSC spontaneously and progressively
increase the production of OPG when differentiat-
ing along the SMC lineage is of particular inter-
est. Moreover, the observation that OPG was pre-
dominantly detected in vascular SMC within the
atherosclerotic plaques, suggests that vascular
SMC play a major role in releasing OPG also in
vivo. Our assumption is nevertheless indirect
because a simultaneous expression for α-actin and
OPG was not assessed at the same time in our
experiments.The potential ability of recombinant
OPG to significantly increase the proliferation
rate of aortic SMC suggests that OPG could act
as an autocrine/paracrine growth factor for vascu-
lar SMC.In the context of our study,it is notewor-
thy that BM-derived MSC are able to engraft all
layers of atherosclerotic plaques but not normal
segments and could play double roles in the
progress of atherosclerosis (Caplice et al., 2003).
Differentiating into EC, they contribute to regen-
erate the damaged endothelial layer, whereas dif-
ferentiating into SMC, they contribute to worsen
the atherosclerotic lesion (Caplice et al., 2003).
Therefore one mechanism by which MSC of bone
marrow origin may contribute to atherosclerotic
progression is through the release of OPG, which
could act as a paracrine/autocrine growth factor
for vascular SMC. OPG could also contribute to
worsen the degree of atherosclerosis by inhibiting
the TNF family member TRAIL (Vitovski et al.,
2007), which displays anti-inflammatory activity
in vitro (Zauli et al., 2003) and anti-atheroscle-
rotic activity in vivo, as documented by studies in
the apo-E null mice model (Secchiero  et al.,
2006b).
In conclusion, our data suggests that OPG pro-
duced by MSC-derived vascular SMC can signifi-
cantly influence the elevated OPG serum levels
and may induce the progression of atherosclerosis
by promoting proliferation of vascular SMC.
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Figure 2. High levels of OPG are
released by BM MSC-derived
SMC and primary aortic SMC.
BM MSC were induced to differ-
entiate into endothelial (MSC-
Endo) and SMC (MSC-SMC).
Culture differentiation was
monitored by immunofluores-
cence analysis of lineage-spe-
cific markers: von Willebrand
Factor for endothelial cells and
α α-SMA for myocytes (both in
green). DAPI was used in all flu-
orescent images to label nuclei
in blue. Original magnification
40X. Release of OPG in culture
supernatants was measured by
ELISA at different time-points of
culture. OPG released by aortic
EC and SMC cultures is also
shown. Measurements were
done in duplicate and normal-
ized for cell number. Data is
expressed as means ± SD of
results from three independent
experiments. 
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